THE SMARTER E EUROPE 2022: INNOVATIVE SOLUTIONS FOR THE ENERGY TRANSITION AND SECURITY OF SUPPLY
Independence from fossil fuels is key for climate protection – and is of relevance for security policy in light of Russia’s war in Ukraine. Europe must make enormous strides towards renewable energies in order to achieve climate targets and ensure security of supply. At The smarter E Europe – Europe's largest platform for the energy industry – 1,450 exhibitors will present innovative products and solutions to 50,000 trade visitors over an exhibition area of 132,000 m2 from May 11 to 13 in Munich.
Rising electricity and gas prices and dependence on Russian gas are giving the energy transition a tailwind. The transition is urgently needed, and possible: photovoltaics (PV) have been successful for two decades, the energy storage industry has been gaining traction for ten years, and electromobility and charging infrastructure are booming. The solutions for an independent energy supply are ready - now it is time to deploy them sustainably. Renewable energy, decentralization, digitalization, sector coupling, smart and networked energy systems as well as smart charging systems and e-mobility are the focus of The smarter E Europe 2022. Another key topic is green hydrogen. At the exhibition, the “Green Hydrogen Forum & Expo” will provide important impetus for bringing hydrogen, fuel cells, electrolysis and power-to-gas technology to the markets at an accelerated pace.
Focus on energy and mobility transition
The smarter E Europe includes four energy exhibitions: Intersolar Europe, ees Europe, Power2Drive Europe and EM-Power Europe. At Intersolar Europe, companies will present cell concepts and modules as well as inverters and solutions for building-integrated PV, agri-PV (simultaneous land use for agriculture and electricity production using PV systems) and floating PV systems. However, solar power alone does not make an energy transition; rather, what is needed is integrated solutions for a full supply of renewable energy 24/7 and across all seasons. The focus of ees Europe 2022 will therefore be on storage technologies, and in particular battery storage and green hydrogen.
Renewable energy and interconnected energy systems are closely linked to the goal of climate neutrality and the need to reassess security of supply. EM-Power Europe will therefore present smart grid solutions, smart buildings and neighborhoods, and digital business models for municipal utilities and energy providers. Power2Drive Europe will demonstrate the interconnectedness of new energies and mobility and explore everything related to the mobility of the future. This includes in particular intelligent charging solutions, vehicle-to-grid technologies, solar charging infrastructure and e-vehicles.
On May 10 – the day before the exhibition opens – visitors to the accompanying specialist conferences will discover all facets of the new energy world. In the evening, the industry innovation drivers will be honored with the Intersolar AWARD, the ees AWARD and The smarter E AWARD. Exhibition forums and workshops will bring visitors together with key industry representatives.
The smarter E Europe, which encompasses the four individual exhibitions will take place from May 11–13, 2022, at Messe München.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220329005519/en/
Contact information
Contact:
Solar Promotion GmbH | PO Box 100 170 | 75101 Pforzheim
Horst Dufner | Tel.: +49 7231 58598-0 | Fax: +49 7231 58598-28
dufner@solarpromotion.de
Press contact:
fischerAppelt, relations | Otl-Aicher-Str. 64 | 80807 Munich
Felizia Rein| Tel. +49 89 74 74 66 40
felizia.rein@fischerappelt.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named Sitecore’s First Global Partner Under Global Elite Reseller Program8.1.2026 10:00:00 EET | Press release
Global IT Corporation FPT announced its appointment as the inaugural Global Elite Reseller under a new initiative from Sitecore that expands upon its successful Global Reseller Program. The Global Elite Reseller Program follows the launch of SitecoreAI, the next-generation digital experience platform that puts artificial intelligence at the center of marketing, unifying content, data, and personalization in one composable platform so organizations can reach, engage, and serve their audience across digital channels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107425261/en/ Representatives from FPT and Sitecore at the Global Elite Reseller signing ceremony. Under the agreement, FPT will hold exclusive reseller rights in Vietnam and non-exclusive rights across select markets in Asia and the Middle East, taking SitecoreAI to market and showing how it helps teams plan, create, and optimize digital experiences using AI as cu
Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 09:00:00 EET | Press release
Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 08:30:00 EET | Press release
4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). The U.S. Food and Drug Administration (FDA) approval marks another strategic step in 4MB’s global clinical deployment across
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo ® in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 08:30:00 EET | Press release
Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnier Leconte, AVP & Managing Director at Organon Northwest Europe. “By offering a new treatment option for patients who cannot tolerate statins, we are helping to close a persistent gap in cardiovascular care—one that disproportionately affects women – whilst reinforcing our mission to deliver impactful treatments for a healthier every day.” Cardiovascular disease i
Azafaros to Present at J.P. Morgan’s 44 th Annual Healthcare Conference8.1.2026 08:00:00 EET | Press release
Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15. The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET. The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann-Pick type C disease ((NPC). Two pivotal Phase 3 studies investigating nizubaglustat in GM1/GM2 gangliosidoses and NPC are currently enrolling, with data expected in 2027. The studies build on positive data from a robust clinical program including the Phase 2 RAINBOW study and the PRONTO natural history study. The Phase 3 studies are financed following the company’s successful completion of €132 million series B round completed in 1H 2025. About nizubaglust
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom